98%
921
2 minutes
20
Objective: To test a multifaceted treatment program for patients with obsessive-compulsive disorder (OCD) who did not respond to regular cognitive behavior therapy (CBT). The treatment addresses several factors that may play a role in maintaining OCD.
Methods: We designed a treatment consisting of a 6-day intensive, individual exposure in vivo with response prevention (ERP) format, with 24 therapist-assisted treatment hours at the patient's home and 12 self-controlled ERP hours, including behavioral activation and family interventions. Next, we investigated the effect (obsessive-compulsive symptoms, comorbidity, functioning, quality of life, OCD-related interaction patterns) and feasibility (dropout, treatment satisfaction, and organization) of this program using pre-post-tests, pre-follow-up tests, and qualitative data from patients, family members, and therapists.
Results: In a sample of 22 participants, obsessive-compulsive symptoms (Y-BOCS pre: 28.7, post: 15.9; Wilcoxon S-R tests P<0.01) improved significantly, as did most other effect measures. Results were largely, but not completely, preserved at 3-month follow-up. There was only 1 dropout. Patients, family members, and therapists were satisfied with the treatment. Implementation of the treatment did not pose difficulties.
Conclusions: In nonresponders with OCD, a multifaceted, brief, intensive home-based ERP program targeting factors maintaining OCD is promising and feasible. Extra care is needed to maintain improvement.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11280449 | PMC |
http://dx.doi.org/10.1097/PRA.0000000000000796 | DOI Listing |
Indian J Psychiatry
August 2025
Department of Psychiatry, Institute of Psychiatry-Centre of Excellence, Kolkata, West Bengal, India.
Supratherapeutic dosing of selective serotonin reuptake inhibitors (SSRIs) in obsessive-compulsive disorder (OCD) is an area of clinical interest, particularly for treatment-resistant cases. Standard SSRI doses often provide insufficient symptom relief, prompting clinicians to explore higher-than-recommended doses. Evidence suggests that supratherapeutic dosing can enhance serotonergic activity, potentially improving treatment response.
View Article and Find Full Text PDFPsychophysiology
September 2025
Department of Human Medicine, Institute for Systems Medicine, MSH Medical School Hamburg, Hamburg, Germany.
Obsessive-compulsive disorder (OCD) has been associated with altered performance monitoring, reflected in enhanced amplitudes of the error-related negativity in the event-related potential. However, this is not specific to OCD, as overactive error processing is also evident in anxiety. Although similar neural mechanisms have been proposed for error and feedback processing, it remains unclear whether the processing of errors as indexed by external feedback, reflected in the feedback-related negativity (FRN), is altered in OCD.
View Article and Find Full Text PDFNeuropsychobiology
September 2025
Introduction: There has been an increasing focus on sex differences in bipolar disorder in recent years, yet much remains to be understood about their impact on clinical characteristics and treatment approaches. The aim of this study is to identify sex differences that could alter diagnosis and treatment strategies, potentially improving patient compliance and outcomes.
Methods: This retrospective study analysed data from interviews with 340 participants (171 men, 169 women; ages ranging from 18 to 82 years) from the BIPFAT/BIPLONG study at the specialised outpatient centre for bipolar disorder at the Medical University of Graz, Austria.
Clin EEG Neurosci
September 2025
Department of Psychiatry, NPI Brain Hospital, Uskudar University, Istanbul, Turkey.
IntroductionObsessive-compulsive disorder (OCD) affects 1.1-1.8% of the population, and adult females are more likely to suffer from it.
View Article and Find Full Text PDFFront Hum Neurosci
August 2025
Center for Drug Discovery and Development Sciences, Research Organization of Science and Technology, Ritsumeikan University, Kyoto, Japan.
Emerging evidence suggests that striatal striosomes play a key role in the dopaminergic regulation of motor and mental action selection processes, with impairments leading to repetitive stereotyped movements (dystonias), thoughts (obsessions), and behaviors (compulsions). To explore this hypothesis therapeutically, we investigated how idiopathic dystonia and obsessive-compulsive disorder (OCD) respond to a novel dopaminergic treatment using low-dose L-DOPA combined with chlorpromazine (CPZ), which can primarily enhance striosomal D dopamine receptor (DR) signaling in humans. The therapeutic effects of L-DOPA/CPZ were assessed over 1 year in 26 idiopathic dystonia patients (mean age, 55.
View Article and Find Full Text PDF